| Literature DB >> 24744811 |
Gui-Hua Yue1, Shao-Yuan Zhuo1, Meng Xia1, Zhuo Zhang2, Yi-Wen Gao2, Yuan Luo2.
Abstract
Objective. Hypertension is one of the most common cardiovascular disorders with high mortality. Here we explored the antihypertension effects of Huanglian Jiedu Decoction (HJD) on thoracic aorta gene expression in spontaneous hypertensive rats. Methods. A rat model of spontaneous hypertension was used. The gene change profile of thoracic aorta after JHD treatment was assessed by GeneChip(GC) analysis using the Agilent Whole Rat Genome Oligo Microarray. Results. Hypertension induced 441 genes upregulated and 417 genes downregulated compared with the normal control group. Treatment of HJD resulted in 76 genes downregulated and 20 genes upregulated. GC data analysis showed that the majority of change genes were involved in immune system process, developmental process, and cell death. Conclusion. Hypertension altered expression of many genes that regulate various biological functions. HJD significantly reduced hypertension and altered the gene expression profiles of SHR rats. These changing genes were involved in many cellular functions such as regulating smooth muscle contraction, Ca(2+) homeostasis, and NO pathway. This study provides the potential novel insights into hypertension and antihypertension effects of HJD.Entities:
Year: 2014 PMID: 24744811 PMCID: PMC3976878 DOI: 10.1155/2014/565784
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Effects of HJD on blood pressure in rats. BP of rat was measured with mmHg unit. There were 8 rats in each group. *P < 0.05 versus SHR group.
Figure 2Hypertension induced gene changes compared with normal control rats. Note: model = spontaneous hypertension rats (SHR) model group, and control = normotensive Wistar-Kyoto rats control group.
Figure 3HJD treatment caused gene changes compared with untreated SHR rats versus SHR. Note: model = spontaneous hypertension rats (SHR) model group; medication = HJD treatment group.
Downregulated genes in hypertension rats.
| Gene | Abbr. | Gene Id | Chro. | FC |
|
|---|---|---|---|---|---|
| DRABUB01 rat DRG library Rattus norvegicus cDNA clone DRABUB01 5′ | — | NA | 9 | 0.097 | 3.86 |
| Similar to RIKEN cDNA 1700001F09 (LOC289957) | — | NA | 15 | 0.092 | 9.47 |
| Mitochondrial ribosomal protein S2 | Mrps2 | 362094 | 3 | 0.081 | 6.49 |
| Q99LR9_MOUSE (Q99LR9) Riok3 protein (fragment), partial (13%) | — | NA | 18 | 0.079 | 6.79 |
| AGENCOURT_26625193 NIH_MGC_253 Rattus norvegicus cDNA clone IMAGE:7304073 5′ | — | NA | 5 | 0.054 | 6.58 |
| Similar to 60S ribosomal protein L19 (LOC316856) | — | NA | Un | 0.053 | 1.40 |
| Solute carrier family 4 (anion exchanger), member 1 | Slc4a1 | 24779 | 10 | 0.051 | 8.24 |
| Cell division cycle 25 homolog A (S. pombe) | Cdc25a | 171102 | 8 | 0.039 | 6.88 |
| Synuclein, alpha (non-A4 component of amyloid precursor) | Snca | 29219 | 4 | 0.029 | 6.00 |
| Unknown | — | NA | 7 | 0.028 | 2.12 |
| Coproporphyrinogen oxidase | Cpox | 304024 | 11 | 0.021 | 2.11 |
| AGENCOURT_70342463 NIH_MGC_368 Rattus norvegicus cDNA clone IMAGE:8376762 5′ | — | NA | 1 | 0.013 | 9.98 |
| Q8FIR6_ECOL6 (Q8FIR6) cytochrome b561 homolog 2, partial (5%) | — | NA | 9 | 0.009 | 2.05 |
| UI-R-C3-sf-g-04-0-UI | — | NA | 1 | 0.007 | 6.28 |
Note. Abbr.: gene abbreviation, Chro.: chromosome, Gene Id represents the identity (ID) of the gene in GenBank; FC = SHR model group gene expression level/normotensive WKY control group expression level. “—/NA/Un” indicates unknown.
Upregulated genes (model versus control).
| Gene | Abbr. | Gene Id | Chro. | FC |
|
|---|---|---|---|---|---|
| Bone gamma-carboxyglutamate (gla) protein | Bglap | 25295 | 2 | 61.402 | 1.96 |
| Uncharacterized protein | — | NA | 2 | 25.856 | 1.96 |
| Unknown | — | NA | 13 | 24.949 | 9.99 |
| Cellular retinoic acid binding protein 2 | Crabp2 | 29563 | 2 | 20.657 | 4.73 |
| Major histocompatibility complex, assembled from 40 BACs, strain Brown Norway (BN/ssNHsd), RT1n haplotype; segment 2/11 | — | NA | 20 | 19.648 | 1.52 |
| V-set domain containing T cell activation inhibitor 1 | Vtcn1 | 295322 | 2 | 18.951 | 1.15 |
| Interferon-induced protein with tetratricopeptide repeats 1 | Ifit1 | 56824 | 1 | 17.991 | 1.51 |
| Unknown | — | NA | 10 | 13.875 | 5.54 |
| Uncharacterized protein | — | NA | 1 | 13.621 | 5.06 |
| Similar to SMAD-interacting zinc finger protein 2 | LOC679126 | 679126 | 13.572 | 8.21 | |
| Transient receptor potential cation channel, subfamily C, member 4 | Trpc4 | 84494 | 2 | 13.374 | 8.20 |
| Q3X0T1_9ACTN (Q3X0T1) 60 kDa innermembrane protein, partial (6%) | — | NA | 19 | 12.417 | 4.35 |
| CJ032_MOUSE (Q9CRC6) protein C10orf32 homolog, partial (15%) | — | NA | 1 | 11.726 | 8.63 |
| TL0ACA45YL24 | — | NA | X | 11.407 | 1.80 |
Note. Abbr.: gene abbreviation, Chro.: chromosome, Gene Id represents the identity (ID) of the gene in GenBank; FC = SHR model group gene expression level/normotensive WKY control group expression level. “—/NA/Un” indicates unknown.
The upregulated and downregulated genes after the treatment of HLJDD.
| Gene | Abbr. | Gene Id | Chro. | FC |
|
|---|---|---|---|---|---|
| Solute carrier family 4 (anion exchanger), member 1 | Slc4a1 | 24779 | 10 | 3.871 | 6.74 |
| Protein phosphatase 1, regulatory subunit 3D | Ppp1r3d | 689995 | 3 | 2.566 | 2.78 |
| Ribonucleotide reductase M2 | Rrm2 | 362720 | 6 | 2.551 | 6.30 |
| pim-1 oncogene | Pim1 | 24649 | 20 | 2.529 | 5.12 |
| Spectrin, beta, erythrocytic | Sptb | 314251 | 6 | 2.470 | 4.66 |
| Transmembrane and coiled-coil domain family 2 | Tmcc2 | 305095 | 13 | 2.444 | 3.38 |
| Unknown | — | NA | 3 | 2.264 | 7.87 |
| UI-R-C4-alc-g-09-0-UI | — | NA | Un | 0.235 | 3.60 |
| UI-R-BJ2-bql-b-07-0-UI | — | NA | 13 | 0.385 | 3.14 |
| Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Kcnh1 | 65198 | 13 | 0.393 | 9.98 |
| Nuclear receptor subfamily 4 group A member 3 | Nr4a3 | 58853 | 5 | 0.456 | 9.87 |
Note. Abbr.: gene abbreviation, Chro.: chromosome, Gene Id represents the identity (ID) of the gene in GenBank; FC = HLJDT treatment group/SHR model group gene expression level. “—/NA/Un” indicates unknown.
Functional catalogers of hypertension-induced gene change profiles.
| GO Id | Term | Hit genes |
|
|---|---|---|---|
| GO:0032501 | Multicellular organismal process | ||
| GO:0051239 | Regulation of multicellular organismal process | 56 | 0.0033 |
| GO:0048771 | Tissue remodeling | 14 | 0.0068 |
| GO:0001816 | Cytokine production | 15 | 0.0243 |
| GO:0003008 | System process | 77 | 0.0485 |
| GO:0032502 | Developmental process | ||
| GO:0001503 | Ossification | 18 | 0.0005 |
| GO:0050793 | Regulation of developmental process | 66 | 0.0045 |
| GO:0051704 | Multiorganism process | ||
| GO:0051707 | Response to other organism | 23 | 0.0026 |
| GO:0044419 | Interspecies interaction between organisms | 7 | 0.0059 |
| GO:0050896 | Response to stimulus | ||
| GO:0009607 | Response to biotic stimulus | 24 | 0.0074 |
| GO:0042221 | Response to chemical stimulus | 97 | 0.0214 |
| GO:0010926 | Anatomical structure formation | ||
| GO:0022607 | Cellular component assembly | 41 | 0.042 |
| GO:0050789 | Regulation of biological process | ||
| GO:0051239 | Regulation of multicellular organismal process | 56 | 0.0033 |
| GO:0050793 | Regulation of developmental process | 66 | 0.0045 |
| GO:0048518 | Positive regulation of biological process | 86 | 0.0361 |
Functional category of HJD-induced gene change profiles.
| GO Id | Term | Hit genes |
|
|---|---|---|---|
| GO:0002376 | Immune system process | ||
| GO:0002520 | Immune system development | 10 | 0.0001 |
| GO:0045321 | Leukocyte activation | 12 | 0.0001 |
| GO:0002682 | Regulation of immune system process | 12 | 0.0001 |
| GO:0006955 | Immune response | 10 | 0.0003 |
| GO:0002684 | Positive regulation of immune system process | 7 | 0.0006 |
| GO:0045058 | T cell selection | 2 | 0.0046 |
| GO:0002253 | Activation of immune response | 3 | 0.026 |
| GO:0009987 | Cellular process | ||
| GO:0001775 | Cell activation | 13 | 0.0001 |
| GO:0008283 | Cell proliferation | 15 | 0.0001 |
| GO:0048522 | Positive regulation of cellular process | 22 | 0.0002 |
| GO:0008219 | Cell death | 13 | 0.0016 |
| GO:0048523 | Negative regulation of cellular process | 16 | 0.0086 |
| GO:0016043 | Cellular component organization | 19 | 0.0181 |
| GO:0007049 | Cell cycle | 7 | 0.0453 |
| GO:0008152 | Metabolic process | ||
| GO:0009058 | Biosynthetic process | 28 | 0.0005 |
| GO:0009893 | Positive regulation of metabolic process | 11 | 0.0361 |
| GO:0006807 | Nitrogen compound metabolic process | 5 | 0.0413 |
| GO:0019748 | Secondary metabolic process | 2 | 0.0423 |
| GO:0032502 | Developmental process | ||
| GO:0050793 | Regulation of developmental process | 17 | 0.0008 |
| GO:0051093 | Negative regulation of developmental process | 10 | 0.0026 |
| GO:0048856 | Anatomical structure development | 21 | 0.0086 |
| GO:0009790 | Embryonic development | 8 | 0.0154 |
| GO:0007275 | Multicellular organismal development | 20 | 0.0249 |
| GO:0001503 | Ossification | 4 | 0.0251 |
| GO:0009653 | Anatomical structure morphogenesis | 12 | 0.0409 |
| GO:0016265 | Death | ||
| GO:0008219 | Cell death | 13 | 0.0016 |
| GO:0032501 | Multicellular organismal process | ||
| GO:0001816 | Cytokine production | 7 | 0.0003 |
| GO:0051240 | Positive regulation of multicellular organismal process | 7 | 0.0017 |
| GO:0051239 | Regulation of multicellular organismal process | 14 | 0.0021 |
| GO:0007275 | Multicellular organismal development | 20 | 0.0249 |
| GO:0050896 | Response to stimulus | ||
| GO:0006955 | Immune response | 10 | 0.0003 |
| GO:0009605 | Response to external stimulus | 11 | 0.0084 |
| GO:0009607 | Response to biotic stimulus | 6 | 0.0201 |
| GO:0048584 | Positive regulation of response to stimulus | 5 | 0.0209 |
| GO:0048585 | Negative regulation of response to stimulus | 3 | 0.0445 |
| GO:0050789 | Regulation of biological process | ||
| GO:0002682 | Regulation of immune system process | 12 | 0.0001 |
| GO:0048518 | Positive regulation of biological process | 24 | 0.0001 |
| GO:0050793 | Regulation of developmental process | 17 | 0.0008 |
| GO:0051239 | Regulation of multicellular organismal process | 14 | 0.0021 |
| GO:0048519 | Negative regulation of biological process | 18 | 0.0045 |
| GO:0032844 | Regulation of homeostatic process | 3 | 0.045 |
| GO:0048518 | Positive regulation of biological process | 24 | 0.0001 |
| GO:0048519 | Negative regulation of biological process | 18 | 0.0045 |
| GO:0010926 | Anatomical structure formation | 12 | 0.0254 |
Hypertension altered genes in 22 KEGG pathways.
| KEGG pathway | Hit genes |
|
|---|---|---|
| Olfactory transduction | 29 | 0 |
| Neuroactive ligand-receptor interaction | 13 | 0.0002 |
| Cytokine-cytokine receptor interaction | 10 | 0.0009 |
| Focal adhesion | 9 | 0.0009 |
| Tight junction | 6 | 0.0061 |
| RIG-I-like receptor signaling pathway | 4 | 0.0081 |
| Ether lipid metabolism | 3 | 0.0083 |
| Calcium signaling pathway | 7 | 0.0086 |
| Leishmania infection | 4 | 0.0089 |
| Amyotrophic lateral sclerosis (ALS) | 4 | 0.0113 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 4 | 0.014 |
| ABC transporters | 3 | 0.0171 |
| Aldosterone-regulated sodium reabsorption | 3 | 0.0213 |
| Hypertrophic cardiomyopathy (HCM) | 4 | 0.0231 |
| Dilated cardiomyopathy | 4 | 0.0247 |
| Glycosphingolipid biosynthesis—ganglio series | 2 | 0.0265 |
| Glutathione metabolism | 3 | 0.0284 |
| Apoptosis | 4 | 0.032 |
| Wnt signaling pathway | 5 | 0.0324 |
| Natural killer cell mediated cytotoxicity | 5 | 0.0339 |
| Maturity onset diabetes of the young | 2 | 0.0415 |
| MAPK signaling pathway | 7 | 0.047 |
HJD altered genes in 10 KEGG pathways.
| KEGG pathway | Hit genes |
|
|---|---|---|
| Hematopoietic cell lineage | 3 | 0.0004 |
| Metabolic pathways | 8 | 0.0016 |
| Natural killer cell mediated cytotoxicity | 3 | 0.0027 |
| NOD-like receptor signaling pathway | 2 | 0.0066 |
| Cytokine-cytokine receptor interaction | 3 | 0.0105 |
| Pyrimidine metabolism | 2 | 0.0148 |
| T cell receptor signaling pathway | 2 | 0.0192 |
| Axon guidance | 2 | 0.0254 |
| Jak-STAT signaling pathway | 2 | 0.0308 |
| Purine metabolism | 2 | 0.0379 |